Reinhard Hohlfeld
Research Subjects
Reinhard Hohlfeld has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Hartmut Wekerle
6 shared publications- Cinthia Farina
Institute of Experimental Neurology and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
5 shared publications - Edgar Meinl
Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München
4 shared publications - Christine Stadelmann
Department of Neuropathology University Medical Center Göttingen Göttingen Germany
3 shared publications - Hans Lassmann
Department of Neuroimmunology, Center for Brain Research Medical University of Vienna Vienna Austria
3 shared publications Martin Kerschensteiner
3 shared publications
Latest Publications
- 1 November 2008
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 274 (1-2) , 5-8
B- and T-cell responses in multiple sclerosis: Novel approaches offer new insights
- 1 November 2008
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 274 (1-2) , 5-8
B- and T-cell responses in multiple sclerosis: Novel approaches offer new insights
- 1 February 2008
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 265 (1-2) , 93-96
Neurotrophic cross-talk between the nervous and immune systems: Relevance for repair strategies in multiple sclerosis?
- 1 February 2008
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 265 (1-2) , 93-96
Neurotrophic cross-talk between the nervous and immune systems: Relevance for repair strategies in multiple sclerosis?
- 1 March 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (S1) , s1-s7
The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis
Autoreactive T cells are a regular component of the healthy immune system. It has been proposed that some of these autoreactive T cells even might have a protective function. Recent studies support this notion by demonstrating that: a) myelin-autoreactive T cells show neuroprotective effects in vivo, and b) activated antigen-specific human T cells and other immune cells produce bioactive brain-derived neurotrophic factor (BDNF) and other neurotrophic factors in vitro. Furthermore, BDNF is expressed in different types of inflammatory cells in brain lesions of patients with acute disseminated leukoencephalopathy or multiple sclerosis. It seems plausible that the immune cell-mediated import of BDNF and other neurotrophic factors into the central nervous system has functional consequences and implications for the therapy of multiple sclerosis and other neuroimmunological diseases.
- 1 March 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (S1) , s1-s7
The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis
Autoreactive T cells are a regular component of the healthy immune system. It has been proposed that some of these autoreactive T cells even might have a protective function. Recent studies support this notion by demonstrating that: a) myelin-autoreactive T cells show neuroprotective effects in vivo, and b) activated antigen-specific human T cells and other immune cells produce bioactive brain-derived neurotrophic factor (BDNF) and other neurotrophic factors in vitro. Furthermore, BDNF is expressed in different types of inflammatory cells in brain lesions of patients with acute disseminated leukoencephalopathy or multiple sclerosis. It seems plausible that the immune cell-mediated import of BDNF and other neurotrophic factors into the central nervous system has functional consequences and implications for the therapy of multiple sclerosis and other neuroimmunological diseases.
- 1 May 2004
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 10 (3_suppl) , S16-S22
Immunologic factors in primary progressive multiple sclerosis
Primary progressive multiple sclerosis (PPMS) is clinically character ized by progression without remission or relapse, in contrast to relapsing forms of MS. Pathologic and imaging findings also indicate that PPMS differs from relapsing forms. Recent studies examining potential immunologic differences among MS forms suggest that cytokine and adhesion molecule expression profiles, but not chemokine recepto r profiles, in PPMS patients resemble those in healthy controls more than those in patients with relapsing MS. However, the significance of these findings remains to be fully elucidated, and there is little additional evidence as yet of marked differences among MS forms based on immunologic characteristics. O f interest are the recent demonstrations that activated immune cells produce brain-derived neurotrophic factor (BDNF), a neuroprotective factor, in MS lesions, that BDNF receptors are located in MS tissue, and that glatiramer acetate (GA)-specific T cells produce BDNF irrespective of T helper cell Th1 or Th2 pheno type. These findings both support the concept of a protective inflammation in MS and suggest an additional mechanism of action for the clinical effects of G A therapy in MS. Whether and to what extent this mechanism is present in different MS forms remain to be clarified.
- 1 May 2004
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 10 (3_suppl) , S16-S22
Immunologic factors in primary progressive multiple sclerosis
Primary progressive multiple sclerosis (PPMS) is clinically character ized by progression without remission or relapse, in contrast to relapsing forms of MS. Pathologic and imaging findings also indicate that PPMS differs from relapsing forms. Recent studies examining potential immunologic differences among MS forms suggest that cytokine and adhesion molecule expression profiles, but not chemokine recepto r profiles, in PPMS patients resemble those in healthy controls more than those in patients with relapsing MS. However, the significance of these findings remains to be fully elucidated, and there is little additional evidence as yet of marked differences among MS forms based on immunologic characteristics. O f interest are the recent demonstrations that activated immune cells produce brain-derived neurotrophic factor (BDNF), a neuroprotective factor, in MS lesions, that BDNF receptors are located in MS tissue, and that glatiramer acetate (GA)-specific T cells produce BDNF irrespective of T helper cell Th1 or Th2 pheno type. These findings both support the concept of a protective inflammation in MS and suggest an additional mechanism of action for the clinical effects of G A therapy in MS. Whether and to what extent this mechanism is present in different MS forms remain to be clarified.
- Open Access
- 6 April 2004
- Published by Oxford University Press (OUP) in Brain
- Vol. 127 (6) , 1370-1378
Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo
It is widely assumed that glatiramer acetate (GA), an approved agent for the immunomodulatory treatment of multiple sclerosis, acts primarily as an antigen for T lymphocytes. Recent studies, however, indicated that in vitro, GA directly inhibits dendritic cells, a rare but potent type of professional antigen‐presenting cell (APC). To investigate whether these in vitro observations are relevant to the actions of GA in vivo, we studied the effects of GA on monocytes, the major type of circulating APC. In a first series of experiments, we investigated the effects of GA on monocyte reactivity in vitro. Monocytes were stimulated with ligands for Toll‐like receptor (TLR)‐2 (peptidoglycan and lipoteichoic acid), TLR‐4 [lipopolysaccharide (LPS)] and TLR‐5 (flagellin), as well as two proinflammatory cytokines (interferon‐γ and granulocyte–monocyte colony‐stimulating factor). Monocyte activation was measured by induction of the surface markers signalling lymphocytic activation molecule (SLAM), CD25 and CD69 (detected by cytofluorometry), and by production of monocyte‐derived tumour necrosis factor (TNF)‐α (detected by enzyme‐linked immunospot assay). GA had a broad inhibitory effect on all measures of monocyte reactivity, regardless of which stimulator was used. It is unlikely that this reflects a simple toxic effect, because monocyte viability and CD14 expression were unaffected. In a second series of experiments, we investigated the properties of monocytes cultured ex vivo from eight GA‐treated multiple sclerosis patients, eight untreated multiple sclerosis patients and eight healthy subjects. We found that LPS‐induced SLAM expression and TNF‐α production were significantly reduced in monocytes from GA‐treated patients compared with controls. These results demonstrate for the first time that GA inhibits monocyte reactivity in vitro and in vivo, significantly extending the current concept of the mechanism of action of GA.
- 6 April 2004
- Published by Oxford University Press (OUP) in Brain
- Vol. 127 (6) , 1370-1378
Open AccessMultiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo
It is widely assumed that glatiramer acetate (GA), an approved agent for the immunomodulatory treatment of multiple sclerosis, acts primarily as an antigen for T lymphocytes. Recent studies, however, indicated that in vitro, GA directly inhibits dendritic cells, a rare but potent type of professional antigen‐presenting cell (APC). To investigate whether these in vitro observations are relevant to the actions of GA in vivo, we studied the effects of GA on monocytes, the major type of circulating APC. In a first series of experiments, we investigated the effects of GA on monocyte reactivity in vitro. Monocytes were stimulated with ligands for Toll‐like receptor (TLR)‐2 (peptidoglycan and lipoteichoic acid), TLR‐4 [lipopolysaccharide (LPS)] and TLR‐5 (flagellin), as well as two proinflammatory cytokines (interferon‐γ and granulocyte–monocyte colony‐stimulating factor). Monocyte activation was measured by induction of the surface markers signalling lymphocytic activation molecule (SLAM), CD25 and CD69 (detected by cytofluorometry), and by production of monocyte‐derived tumour necrosis factor (TNF)‐α (detected by enzyme‐linked immunospot assay). GA had a broad inhibitory effect on all measures of monocyte reactivity, regardless of which stimulator was used. It is unlikely that this reflects a simple toxic effect, because monocyte viability and CD14 expression were unaffected. In a second series of experiments, we investigated the properties of monocytes cultured ex vivo from eight GA‐treated multiple sclerosis patients, eight untreated multiple sclerosis patients and eight healthy subjects. We found that LPS‐induced SLAM expression and TNF‐α production were significantly reduced in monocytes from GA‐treated patients compared with controls. These results demonstrate for the first time that GA inhibits monocyte reactivity in vitro and in vivo, significantly extending the current concept of the mechanism of action of GA.
- 1 November 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (11) , 1587-1592
Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis
Recently we described an enzyme-linked immunoadsorbent spot (ELISPOT) assay allowing us to define an immunological response profile observed in multiple sclerosis patients treated with Copaxone (glatiramer acetate; GA) but not untreated subjects [4]. The profile encompasses three criteria, a) reduced proliferative response to GA (as observed with a standard primary proliferation assay); b) strong in vitro activation of interferon-γ-producing T cells at high concentrations of GA (as detected by interferon-γ ELISPOT); and c) activation of interleukin–4-producing T cells over a wider range of concentrations of GA (as detected by interleukin–4 ELISPOT). It is at present unknown whether the immunological response to GA correlates with the clinical response. To address this question we performed the pilot study reported here. We asked the major German multiple sclerosis centres to send us blood samples from all GA-treated patients who were going to discontinue treatment because of treatment failure. The clinical nonresponders either had an unchanged or increased exacerbation rate, or developed a secondary progressive course during GA treatment. Over more than one year, we prospectively collected 9 samples from clinical non-responders. We compared the immune response to GA of peripheral blood mononuclear cells from the 9 clinical nonresponders with 15 clinical responders, using a standard proliferation assay combined with ELISPOT assays for detection of interferon-γ and interleukin–4 secreting cells. Thirteen (86 %) of the 15 clinical responders met at least 2 of the immunological response criteria mentioned above. In contrast, only 2 (22 %) of the 9 clinical nonresponders met two of the immunological criteria (p = 0.0006). We conclude that the ELISPOT assay may provide a promising additional tool for monitoring the treatment response in multiple sclerosis patients treated with GA.
- 1 November 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (11) , 1587-1592
Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis
Recently we described an enzyme-linked immunoadsorbent spot (ELISPOT) assay allowing us to define an immunological response profile observed in multiple sclerosis patients treated with Copaxone (glatiramer acetate; GA) but not untreated subjects [4]. The profile encompasses three criteria, a) reduced proliferative response to GA (as observed with a standard primary proliferation assay); b) strong in vitro activation of interferon-γ-producing T cells at high concentrations of GA (as detected by interferon-γ ELISPOT); and c) activation of interleukin–4-producing T cells over a wider range of concentrations of GA (as detected by interleukin–4 ELISPOT). It is at present unknown whether the immunological response to GA correlates with the clinical response. To address this question we performed the pilot study reported here. We asked the major German multiple sclerosis centres to send us blood samples from all GA-treated patients who were going to discontinue treatment because of treatment failure. The clinical nonresponders either had an unchanged or increased exacerbation rate, or developed a secondary progressive course during GA treatment. Over more than one year, we prospectively collected 9 samples from clinical non-responders. We compared the immune response to GA of peripheral blood mononuclear cells from the 9 clinical nonresponders with 15 clinical responders, using a standard proliferation assay combined with ELISPOT assays for detection of interferon-γ and interleukin–4 secreting cells. Thirteen (86 %) of the 15 clinical responders met at least 2 of the immunological response criteria mentioned above. In contrast, only 2 (22 %) of the 9 clinical nonresponders met two of the immunological criteria (p = 0.0006). We conclude that the ELISPOT assay may provide a promising additional tool for monitoring the treatment response in multiple sclerosis patients treated with GA.
- Open Access
- 1 November 2002
- Published by Oxford University Press (OUP) in Brain
- Vol. 125 (11) , 2381-2391
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
The clinical effects of glatiramer acetate (GA), an approved therapy for multiple sclerosis, are thought to be largely mediated by a T‐helper 1 (TH1) to T‐helper 2 (TH2) shift of GA‐reactive T‐lymphocytes. Current theories propose that activated GA‐reactive TH2 cells penetrate the CNS, release anti‐inflammatory cytokines such as interleukin (IL)‐4, IL‐5 and IL‐10, and thus inhibit neighbouring inflammatory cells by a mechanism termed ‘bystander suppression’. We demonstrate that both GA‐specific TH2 and TH1 cells produce the neurotrophin brain‐derived neurotrophic factor (BDNF). As the signal‐transducing receptor for BDNF, the full‐length 145 tyrosine kinase receptor (trk) B, is expressed in multiple sclerosis lesions, it is likely that the BDNF secreted by GA‐reactive TH2 and TH1 has neurotrophic effects in the multiple sclerosis target tissue. This may be an additional mechanism of action of GA, and may be relevant for therapies with altered peptide ligands in general. To demonstrate that GA‐reactive T cells produce BDNF, we selected four GA‐specific, long‐term T‐cell lines (TCLs), which were characterized according to their cytokine profile by intracellular double‐fluorescence flow cytometry. Three TCLs (isolated from a normal subject) had the phenotypes TH1, TH1/TH0, and TH0; the fourth, derived from a GA‐treated patient, had the phenotype TH2. To demonstrate BDNF production, we used a combination of RT‐PCR (reverse transcription‐polymerase chain reaction) and two specially designed techniques for BDNF protein detection: one was based on ELISA (enzyme‐linked immunosorbent assay) of supernatants from co‐cultures of GA‐specific TCLs plus GA‐pulsed antigen‐presenting cells, and the other on the direct intracellular staining of BDNF in individual T cells and flow cytometric analysis. The different assays and different TCLs yielded similar, consistent results. All four GA‐specific T‐cell lines, representing the major different TH phenotypes, could be stimulated to produce BDNF.
- 1 November 2002
- Published by Oxford University Press (OUP) in Brain
- Vol. 125 (11) , 2381-2391
Open AccessGlatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
The clinical effects of glatiramer acetate (GA), an approved therapy for multiple sclerosis, are thought to be largely mediated by a T‐helper 1 (TH1) to T‐helper 2 (TH2) shift of GA‐reactive T‐lymphocytes. Current theories propose that activated GA‐reactive TH2 cells penetrate the CNS, release anti‐inflammatory cytokines such as interleukin (IL)‐4, IL‐5 and IL‐10, and thus inhibit neighbouring inflammatory cells by a mechanism termed ‘bystander suppression’. We demonstrate that both GA‐specific TH2 and TH1 cells produce the neurotrophin brain‐derived neurotrophic factor (BDNF). As the signal‐transducing receptor for BDNF, the full‐length 145 tyrosine kinase receptor (trk) B, is expressed in multiple sclerosis lesions, it is likely that the BDNF secreted by GA‐reactive TH2 and TH1 has neurotrophic effects in the multiple sclerosis target tissue. This may be an additional mechanism of action of GA, and may be relevant for therapies with altered peptide ligands in general. To demonstrate that GA‐reactive T cells produce BDNF, we selected four GA‐specific, long‐term T‐cell lines (TCLs), which were characterized according to their cytokine profile by intracellular double‐fluorescence flow cytometry. Three TCLs (isolated from a normal subject) had the phenotypes TH1, TH1/TH0, and TH0; the fourth, derived from a GA‐treated patient, had the phenotype TH2. To demonstrate BDNF production, we used a combination of RT‐PCR (reverse transcription‐polymerase chain reaction) and two specially designed techniques for BDNF protein detection: one was based on ELISA (enzyme‐linked immunosorbent assay) of supernatants from co‐cultures of GA‐specific TCLs plus GA‐pulsed antigen‐presenting cells, and the other on the direct intracellular staining of BDNF in individual T cells and flow cytometric analysis. The different assays and different TCLs yielded similar, consistent results. All four GA‐specific T‐cell lines, representing the major different TH phenotypes, could be stimulated to produce BDNF.
- Open Access
- 1 February 2002
- Published by BMJ in Practical Neurology
- Vol. 2 (1) , 4-11
Myositis Diagnosis and Management
INTRODUCTION The inflammatory myopathies comprise a group of acquired myopathies in which muscle weakness and inflammatory infiltrates are the principal clinical and histological findings. Traditionally, a distinction is made between polymyositis, dermatomyositis and inclusion body myositis. This brief review will focus on polymyositis. CLINICAL FEATURES Diagnostic criteria Polymyositis is characterized by symmetrical proximal muscle weakness. Respiratory, pharyngeal and neck muscles may also be involved during later stages of the disease (Dalakas & Sivakumar 1996; Mantegazza et al. 1997; Dalakas 1998a). Up to half the patients suffer from muscle pain or arthralgia. The history, clinical symptoms and signs, elevated serum levels of muscle enzymes, electrophysiological changes and histological findings together provide the basis for the diagnosis. The main diagnostic criteria and features are summarized in Table 1 for polymyositis and for the two other forms of idiopathic inflammatory myopathies, dermatomyositis, and inclusion body myositis. Clinically, poylmyositis and dermatomyositis are distinguished by
- 1 February 2002
- Published by BMJ in Practical Neurology
- Vol. 2 (1) , 4-11
Open AccessMyositis Diagnosis and Management
INTRODUCTION The inflammatory myopathies comprise a group of acquired myopathies in which muscle weakness and inflammatory infiltrates are the principal clinical and histological findings. Traditionally, a distinction is made between polymyositis, dermatomyositis and inclusion body myositis. This brief review will focus on polymyositis. CLINICAL FEATURES Diagnostic criteria Polymyositis is characterized by symmetrical proximal muscle weakness. Respiratory, pharyngeal and neck muscles may also be involved during later stages of the disease (Dalakas & Sivakumar 1996; Mantegazza et al. 1997; Dalakas 1998a). Up to half the patients suffer from muscle pain or arthralgia. The history, clinical symptoms and signs, elevated serum levels of muscle enzymes, electrophysiological changes and histological findings together provide the basis for the diagnosis. The main diagnostic criteria and features are summarized in Table 1 for polymyositis and for the two other forms of idiopathic inflammatory myopathies, dermatomyositis, and inclusion body myositis. Clinically, poylmyositis and dermatomyositis are distinguished by
- 1 February 2002
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 123 (1-2) , 188-192
Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients
- 1 February 2002
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 123 (1-2) , 188-192
Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients
- 1 June 2001
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 14 (3) , 299-304
Immunological update on multiple sclerosis
The present review of the recent literature focuses on antigen-specific immune reactions in multiple sclerosis. New techniques have allowed precise quantitative analysis of the antigen-receptor repertoire of infiltrating T cells in the multiple sclerosis brain. Novel candidate autoantigens, including B-cell autoantigens, have been identified. ‘Humanized’ animal models allow the functional characterization of human immune molecules in vivo. Finally, several therapeutic trials have recently assessed the clinical benefit of selective immunotherapies.
- 1 June 2001
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 14 (3) , 299-304
Immunological update on multiple sclerosis
The present review of the recent literature focuses on antigen-specific immune reactions in multiple sclerosis. New techniques have allowed precise quantitative analysis of the antigen-receptor repertoire of infiltrating T cells in the multiple sclerosis brain. Novel candidate autoantigens, including B-cell autoantigens, have been identified. ‘Humanized’ animal models allow the functional characterization of human immune molecules in vivo. Finally, several therapeutic trials have recently assessed the clinical benefit of selective immunotherapies.